{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:24:09Z","timestamp":1794349449661,"version":"4.9.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 Training Grant ES-09250"],"award-info":[{"award-number":["T32 Training Grant ES-09250"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008102","name":"University of Cincinnati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016141","name":"Segal Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117552","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:47:28Z","timestamp":1790358448000},"page":"117552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3671-140X","authenticated-orcid":false,"given":"Harry C.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3039-7240","authenticated-orcid":false,"given":"Kate M.","family":"Von Handorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-0884","authenticated-orcid":false,"given":"Catherine A.","family":"Behrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-7290","authenticated-orcid":false,"given":"Justin D.","family":"Lathia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-1400","authenticated-orcid":false,"given":"David R.","family":"Plas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117552_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib2","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.3390\/cancers13194864","article-title":"AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew","volume":"13","author":"Auyez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-07-0862","article-title":"Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme","volume":"14","author":"Hutterer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib4","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-17-2433","article-title":"Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma","volume":"78","author":"Sadahiro","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cancers12071850","article-title":"Gas6\/Axl Signaling Pathway in the Tumor Immune Microenvironment","volume":"12","author":"Tanaka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117552_bib7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/leu.2013.371","article-title":"GAS6 expression identifies high-risk adult AML patients: potential implications for therapy","volume":"28","author":"Whitman","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117552_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114324","article-title":"AXL\/GAS6 signaling governs differentiation of tumor-associated macrophages in breast cancer","volume":"444","author":"Purohit","year":"2025","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.isci.2026.117552_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.07.010","article-title":"AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer","volume":"138","author":"Cardone","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41416-025-03218-8","article-title":"Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL\/STAT3\/ABCG1 in gastric cancer","volume":"134","author":"Kim","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1121130","article-title":"Gas6\/AXL pathway: immunological landscape and therapeutic potential","volume":"13","author":"Zhai","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-15-1458","article-title":"Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy","volume":"22","author":"Scaltriti","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib14","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-24-3841","article-title":"AXL Tyrosine Kinases: A Growing Isoform Family That Promotes Cancer Pathogenesis","volume":"85","author":"Eriksen Gjerstad","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib15","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1038\/s41467-020-17415-x","article-title":"AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network","volume":"11","author":"Abu-Thuraia","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2010.326","article-title":"Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members","volume":"131","author":"Papadakis","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.isci.2026.117552_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869676","article-title":"Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition","volume":"13","author":"Engelsen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tibs.2017.06.004","article-title":"Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands","volume":"42","author":"Lemke","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.isci.2026.117552_bib19","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117552_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","article-title":"How macrophages deal with death","volume":"19","author":"Lemke","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI1112","article-title":"Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF","volume":"101","author":"Fadok","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.isci.2026.117552_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2008.05343.x","article-title":"In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation","volume":"106","author":"Weinger","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.isci.2026.117552_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","article-title":"TAM receptors are pleiotropic inhibitors of the innate immune response","volume":"131","author":"Rothlin","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117552_bib24","doi-asserted-by":"crossref","first-page":"15397","DOI":"10.1074\/jbc.RA118.003063","article-title":"HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2026.117552_bib178","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1038\/oncsis.2016.66","article-title":"Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells","volume":"5","author":"Vouri","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.isci.2026.117552_bib86","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3K\u03b1 inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117552_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk2746","article-title":"Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer","volume":"8","author":"Adam-Artigues","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.isci.2026.117552_bib25","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clim.2016.05.011","article-title":"Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE","volume":"169","author":"Orme","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/biom11050660","article-title":"Proteolytic Cleavage of Receptor Tyrosine Kinases","volume":"11","author":"Huang","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2026.117552_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227187","article-title":"Soluble AXL as a marker of disease progression and survival in melanoma","volume":"15","author":"Flem-Karlsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117552_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024596118","article-title":"The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion","volume":"118","author":"Zd\u017calik-Bielecka","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117552_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00018-022-04312-3","article-title":"Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation","volume":"79","author":"Po\u015bwiata","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2026.117552_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2026.117552_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbrc.2005.05.086","article-title":"Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation","volume":"333","author":"Valverde","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13560","article-title":"E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy","volume":"204","author":"Jafari","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-22-0376","article-title":"LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL","volume":"13","author":"Ko","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117552_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqag001","article-title":"Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies","volume":"7","author":"Adedayo","year":"2026","journal-title":"Oxford Open Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib36","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","article-title":"Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages","volume":"148","author":"Fadok","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.18","article-title":"Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells","volume":"6","author":"Dransfield","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117552_bib38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","article-title":"TAM family kinases as therapeutic targets at the interface of cancer and immunity","volume":"20","author":"DeRyckere","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib39","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1086\/520594","article-title":"The mechanism of Axl-mediated Ebola virus infection","volume":"196","author":"Shimojima","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.isci.2026.117552_bib40","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1128\/JVI.00354-15","article-title":"Biology of Zika Virus Infection in Human Skin Cells","volume":"89","author":"Hamel","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117552_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","article-title":"AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.117552_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156120","article-title":"AXL in cardiovascular diseases: Pathophysiological insights and clinical perspectives","volume":"272","author":"Qian","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.isci.2026.117552_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","article-title":"Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer\u2019s disease: results from the DELCODE study","volume":"15","author":"Brosseron","year":"2023","journal-title":"Alz. Res. Therapy"},{"key":"10.1016\/j.isci.2026.117552_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.celrep.2016.12.045","article-title":"Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses","volume":"18","author":"Meertens","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers17060994","article-title":"Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer","volume":"17","author":"Kostecki","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fimmu.2011.00057","article-title":"Modulation of macrophage efferocytosis in inflammation","volume":"2","author":"Korns","year":"2011","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2024941","article-title":"MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression","volume":"11","author":"Lin","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.isci.2026.117552_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117552_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13058-025-02015-8","article-title":"AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization","volume":"27","author":"Phi","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib53","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41401-022-01047-6","article-title":"AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage","volume":"44","author":"Pei","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2026.117552_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113067","article-title":"AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages","volume":"42","author":"Hung","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12032-024-02561-9","article-title":"The AXL-mediated modulation of myeloid-derived suppressor cells (MDSC) in nasopharyngeal carcinoma","volume":"42","author":"Lv","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib56","article-title":"Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib57","first-page":"1","article-title":"Growth Arrest-Specific 6 Enhances the Suppressive Function of CD4+CD25+ Regulatory T Cells Mainly through Axl Receptor","volume":"2017","author":"Zhao","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.isci.2026.117552_bib58","doi-asserted-by":"crossref","first-page":"89761","DOI":"10.18632\/oncotarget.21125","article-title":"Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117552_bib59","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/cells9091960","article-title":"Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles","volume":"9","author":"Davis","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.117552_bib60","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117552_bib61","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/brainsci13091269","article-title":"The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets","volume":"13","author":"Ren","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.isci.2026.117552_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1267\/ahc.22-00018","article-title":"Morphologic Analysis of M2 Macrophage in Glioblastoma: Involvement of Macrophage Extracellular Traps (METs)","volume":"55","author":"Michiba","year":"2022","journal-title":"Acta Histochem. Cytoc."},{"key":"10.1016\/j.isci.2026.117552_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/nan.12428","article-title":"Tumour-associated microglia\/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype","volume":"44","author":"S\u00f8rensen","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.isci.2026.117552_bib64","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117552_bib65","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.21873\/anticanres.14947","article-title":"Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma","volume":"41","author":"Kang","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12967-024-04930-4","article-title":"Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells","volume":"22","author":"Victorio","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.117552_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194821","article-title":"A Novel Selective Axl\/Mer\/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment","volume":"14","author":"Jeon","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12943-019-0953-y","article-title":"Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas","volume":"18","author":"Tsukita","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/1541-7786.MCR-16-0350","article-title":"Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression","volume":"15","author":"Kasikara","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib70","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1158\/1078-0432.CCR-21-0972","article-title":"Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade","volume":"27","author":"Terry","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib71","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s12072-023-10572-3","article-title":"Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells","volume":"18","author":"Tanaka","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.isci.2026.117552_bib72","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.immuni.2023.07.015","article-title":"CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117552_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","article-title":"Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117552_bib74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.21873\/cdp.10455","article-title":"The Role of Axl Inhibition and Immune Checkpoint Blockade in Non-small Cell Lung Cancer: Current Understanding and Treatment Strategies","volume":"5","author":"Kim","year":"2025","journal-title":"Cancer Diagn. Progn."},{"key":"10.1016\/j.isci.2026.117552_bib134","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib75","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/s41598-022-12995-8","article-title":"AXL\/CDCP1\/SRC axis confers acquired resistance to osimertinib in lung cancer","volume":"12","author":"Murakami","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117552_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117067","article-title":"AXL enhances the self-renewal of cancer stem-like cells and Osimertinib chemoresistance by regulating SCD1 in non-small cell lung cancer","volume":"240","author":"Pan","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2026.117552_bib140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/1535-7163.MCT-24-0440","article-title":"AXL Kinase Inhibition Promotes Cytosolic DNA Sensor cGAS Activity and Sensitizes Poorly Immunogenic Tumors to Chemo-Immunotherapy","volume":"25","author":"Dhakal","year":"2026","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.117552_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108853","article-title":"AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer","volume":"210","author":"Ancel","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib79","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib127","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","article-title":"AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma","volume":"37","author":"Zuo","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117552_bib80","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib84","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/1878-0261.13749","article-title":"Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3\/ITD acute myeloid leukemia","volume":"19","author":"Seale","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib120","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/onc.2013.57","article-title":"AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells","volume":"33","author":"Asiedu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117552_bib179","article-title":"Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer","volume":"5","author":"Cruz","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.117552_bib174","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-024-02210-9","article-title":"AXL: shapers of tumor progression and immunosuppressive microenvironments","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib143","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI85610","article-title":"Inhibition of the GAS6\/AXL pathway augments the efficacy of chemotherapies","volume":"127","author":"Kariolis","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.isci.2026.117552_bib89","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-19-3142","article-title":"AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer","volume":"26","author":"McDaniel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib88","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib175","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","article-title":"AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma","volume":"21","author":"Brand","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib90","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12885-022-09511-6","article-title":"AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer","volume":"22","author":"Iida","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib91","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-13-0170","article-title":"Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib","volume":"12","author":"Giles","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.117552_bib92","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","article-title":"Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer","volume":"23","author":"Skinner","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41416-018-0373-6","article-title":"Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma","volume":"120","author":"Pinato","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1238883","article-title":"Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma","volume":"13","author":"Breitenecker","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib95","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.18632\/aging.204867","article-title":"Galectin-1-mediated MET\/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis","volume":"15","author":"Hsu","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.isci.2026.117552_bib96","article-title":"AXL inhibition prevents RPA2\/CHK1-mediated homologous recombination to increase PARP inhibitor sensitivity in hepatocellular carcinoma","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.isci.2026.117552_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","article-title":"Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma","volume":"23","author":"Bae","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib99","article-title":"AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers","volume":"10","author":"Ishida","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib98","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/cas.14089","article-title":"Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells","volume":"110","author":"Yoshioka","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.isci.2026.117552_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71869","article-title":"TYRO3, AXL, MERTK and Their Ligands in Brain Metastases From Colorectal Cancers","volume":"15","author":"Noblanc","year":"2026","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2026.117552_bib139","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.celrep.2019.11.018","article-title":"A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis","volume":"29","author":"Hoj","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib124","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.celrep.2018.04.019","article-title":"The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression","volume":"23","author":"Goyette","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.stemcr.2015.03.005","article-title":"Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells","volume":"4","author":"Cheng","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib106","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-12-1557","article-title":"Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition","volume":"19","author":"Piao","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146823","article-title":"Strong Expression of Hypoxia-Inducible Factor-1\u03b1 (HIF-1\u03b1) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer","volume":"11","author":"Nalwoga","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117552_bib108","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.26882","article-title":"Axl signaling is an important mediator of tumor angiogenesis","volume":"10","author":"Tanaka","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117552_bib109","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1038\/onc.2009.212","article-title":"Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis","volume":"28","author":"Li","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117552_bib110","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1158\/0008-5472.CAN-05-0993","article-title":"Multiple roles for the receptor tyrosine kinase axl in tumor formation","volume":"65","author":"Holland","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib111","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/emboj.2012.21","article-title":"Axl is essential for VEGF-A-dependent activation of PI3K\/Akt","volume":"31","author":"Ruan","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2026.117552_bib112","doi-asserted-by":"crossref","first-page":"50403","DOI":"10.18632\/oncotarget.18468","article-title":"Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival","volume":"8","author":"Onken","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117552_bib113","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1073\/pnas.0510923103","article-title":"Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival","volume":"103","author":"Vajkoczy","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117552_bib114","doi-asserted-by":"crossref","first-page":"9876","DOI":"10.18632\/oncotarget.7130","article-title":"Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo","volume":"7","author":"Onken","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117552_bib115","article-title":"Lipocalin 2 orchestrates resistance to ferroptosis via AXL","volume":"45","author":"Wang","year":"2026","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib116","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1097\/TP.0000000000005036","article-title":"Gas6\/AXL Alleviates Hepatic Ischemia\/Reperfusion Injury by Inhibiting Ferroptosis via the PI3K\/AKT Pathway","volume":"108","author":"Zhan","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.isci.2026.117552_bib117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/pcmr.13009","article-title":"The role of ferroptosis in melanoma","volume":"35","author":"Talty","year":"2022","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.isci.2026.117552_bib118","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1038\/s41598-022-09078-z","article-title":"AXL inhibition improves BRAF-targeted treatment in melanoma","volume":"12","author":"Nyakas","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117552_bib119","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/cancers13071521","article-title":"The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications","volume":"13","author":"Wium","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib121","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/iub.1285","article-title":"Axl mediates tumor invasion and chemosensitivity through PI3K\/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma","volume":"66","author":"Li","year":"2014","journal-title":"IUBMB Life"},{"key":"10.1016\/j.isci.2026.117552_bib122","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3892\/etm.2017.4532","article-title":"Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer","volume":"14","author":"Ying","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.isci.2026.117552_bib123","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117552_bib103","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/etm.2023.12147","article-title":"Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype","volume":"26","author":"Ji","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.isci.2026.117552_bib125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/13543784.2025.2511178","article-title":"Prospects of current AXL-targeting therapies in early phase cancer trials","volume":"34","author":"Yim","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.isci.2026.117552_bib126","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2026.117552_bib81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1535-7163.MCT-18-0537","article-title":"Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer","volume":"18","author":"Quinn","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.117552_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217984","article-title":"Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress","volume":"633","author":"Sabarwal","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.117552_bib129","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.4584","article-title":"A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma","volume":"20","author":"Guo","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.isci.2026.117552_bib131","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.celrep.2017.02.022","article-title":"Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia","volume":"18","author":"Liu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117552_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2026.117552_bib132","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/2767-9764.CRC-23-0631","article-title":"Coordinated Targeting of S6K1\/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma","volume":"4","author":"Behrmann","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.811247","article-title":"The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges","volume":"12","author":"Sang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib76","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2502778122","article-title":"ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer","volume":"122","author":"Cui","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117552_bib77","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells","volume":"3","author":"Li","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.117552_bib78","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/ijc.34429","article-title":"Basal-like mammary carcinomas stimulate cancer stem cell properties through AXL-signaling to induce chemotherapy resistance","volume":"152","author":"Pantelaiou-Prokaki","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib137","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib104","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ccell.2024.08.015","article-title":"Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain","volume":"42","author":"Gan","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117552_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107291","article-title":"Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"182","author":"Bhalla","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2026.117552_bib153","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/s41467-025-58179-6","article-title":"Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b\/2a trial","volume":"16","author":"Loges","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117552_bib142","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/ph18121898","article-title":"First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours","volume":"18","author":"Zhang","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.isci.2026.117552_bib162","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1038\/onc.2010.268","article-title":"An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies","volume":"29","author":"Ye","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117552_bib163","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1158\/1078-0432.CCR-16-1316","article-title":"Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis","volume":"23","author":"Leconet","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib155","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.08.020","article-title":"Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer","volume":"163","author":"Fuh","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109801","article-title":"Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer","volume":"27","author":"Knisely","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.117552_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf138","article-title":"Phase 1b\/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma","volume":"30","author":"Beckermann","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117552_bib147","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1535-7163.MCT-21-0704","article-title":"GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis","volume":"21","author":"Bruce","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.117552_bib148","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1158\/1078-0432.CCR-24-3028","article-title":"Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone","volume":"31","author":"Chiu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117552_bib173","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2025.11.001","article-title":"AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer","volume":"204","author":"Tankou","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib144","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117552_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128199","article-title":"Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer","volume":"4","author":"Koopman","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.117552_bib176","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","article-title":"Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers","volume":"21","author":"Zammarchi","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.117552_bib150","first-page":"OF1","article-title":"Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma","author":"Humtsoe","year":"2026","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.117552_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101408","article-title":"The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance","volume":"87","author":"Immordino","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.isci.2026.117552_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118955","article-title":"Discovery of NTQ2494, a potent and orally bioavailable inhibitor of AXL kinase for the treatment of human tumors","volume":"315","author":"Zhang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.117552_bib154","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nchembio.1636","article-title":"An engineered Axl \u201cdecoy receptor\u201d effectively silences the Gas6-Axl signaling axis","volume":"10","author":"Kariolis","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.isci.2026.117552_bib149","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fimmu.2017.01521","article-title":"Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6","volume":"8","author":"Geng","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117552_bib157","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/cdd.2016.11","article-title":"Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer","volume":"23","author":"Birge","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2026.117552_bib158","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12964-020-0521-5","article-title":"TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy","volume":"18","author":"Dayoub","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2026.117552_bib159","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41586-026-10266-4","article-title":"Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion","volume":"653","author":"Medina","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117552_bib160","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00424-024-02948-7","article-title":"Phosphatidylserine externalization as immune checkpoint in cancer","volume":"476","author":"Kur","year":"2024","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.isci.2026.117552_bib161","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12964-025-02090-6","article-title":"Dys-regulated phosphatidylserine externalization as a cell intrinsic immune escape mechanism in cancer","volume":"23","author":"Pulica","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2026.117552_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36401\/JIPO-24-37","article-title":"AXL Inhibitors in Oncology Clinical Trials: A Review","volume":"9","author":"Quach","year":"2025","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib166","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/0118715206351185241209053053","article-title":"Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy","volume":"25","author":"Shah","year":"2025","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.isci.2026.117552_bib167","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.2174\/0109298673382005250828124053","article-title":"RTK AXL and its Isoforms: Regulation and Implications in Cancer","volume":"33","author":"Malikova","year":"2026","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.isci.2026.117552_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2014.12.001","article-title":"Gender differences in plasma growth arrest-specific protein 6 levels in adult subjects","volume":"441","author":"Hung","year":"2015","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.isci.2026.117552_bib169","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.cell.2024.08.013","article-title":"Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy","volume":"187","author":"Chhabra","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117552_bib170","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1023\/A:1011126330233","article-title":"Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast","volume":"12","author":"Berclaz","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117552_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1212104","article-title":"AXL\/Gas6 signaling mechanisms in the hypothalamic-pituitary-gonadal axis","volume":"14","author":"Mohammadzadeh","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.isci.2026.117552_bib180","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/pros.24416","article-title":"Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling","volume":"82","author":"Brown","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.isci.2026.117552_bib172","article-title":"Integrated analysis of sex differences in human dendritic cell, monocyte, and natural killer cell subsets","volume":"17","author":"Yang","year":"2026","journal-title":"Front. Immunol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:34:40Z","timestamp":1794346480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226029317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":172,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226029317"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117552","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117552"}}